Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
UK Legal Reference
UK peptide law — plain-English reference
Cautious summaries of how UK regulators treat peptides — licensed medicines, prescription-only medicines, unlicensed compounds, clinic advertising, fake pens, personal import, and sport. None of this is legal advice. For your specific situation, consult a qualified solicitor. For the wider safety and ethics picture alongside the law, see our safety, legal & ethics overview.
Available now
Are peptides legal in the UK?
An overview of how UK law treats peptides — licensed medicines, prescription-only medicines, unlicensed compounds, 'research only' labelling, advertising, and personal import.
Research peptides and UK law
What 'research use only' and 'not for human consumption' actually mean, how the MHRA looks at presentation and intended purpose, and what this means for sellers, clinics, consumers, and athletes.
“Not for human consumption” claims
The label has no special status under UK medicines law. What it does, what it doesn't, and why the surrounding presentation is what regulators actually look at.
Are peptide clinics legal in the UK?
The three regulatory layers a UK peptide clinic must satisfy — GMC prescriber, GPhC pharmacy, CQC premises — and how to tell a real lawful clinic from a regulated-looking shopfront.
Peptide advertising rules in the UK
CAP / BCAP codes, ASA jurisdiction, POM advertising restrictions, unlicensed-substance medicinal claims, and influencer rules — the three overlapping regimes that govern UK peptide adverts.
Can UK clinics prescribe compounded peptides?
The UK ‘specials’ framework is narrow and prescriber-led. ‘Compounded semaglutide’ marketed on price is a different thing entirely — and an MHRA enforcement priority.
MHRA enforcement and unlicensed medicines
How the MHRA enforces UK medicines law — the statutory offences under HMR 2012, the Criminal Enforcement Unit, what triggers action, and how reports are made and triaged.
Prescription-only medicines and GLP-1 drugs
Every licensed UK GLP-1 is a POM. What POM status means in practice — lawful access, supply offences, advertising restrictions, and the grey market for ‘research-grade’ versions.
Semaglutide and UK law
Semaglutide is a UK prescription-only medicine when used as a medicine. Lawful access, NICE / NHS framing, counterfeit-pen risk, and what 'research only' semaglutide really means.
Tirzepatide and UK law
Tirzepatide (Mounjaro) is a UK prescription-only medicine. The licensed indications, NHS access via NICE, private access, and the unlicensed grey market.
Retatrutide UK legal status
Retatrutide is an investigational drug, not approved anywhere. ‘Research-grade retatrutide’ is unlicensed-medicine supply with no licensed reference product to compare against.
Melanotan UK legal status
Melanotan I and II have one of the clearest UK regulatory positions: unlicensed, repeatedly warned against by MHRA, and with a documented safety profile that includes melanoma case reports.
BPC-157 legal status in the UK
BPC-157 is not a licensed UK medicine. What that means for sellers, clinics, consumers, and athletes — and why 'research use only' wording does not by itself resolve the regulatory question.
TB-500 UK legal status
TB-500 (thymosin beta-4 fragment) is unlicensed in the UK and prohibited under WADA S2. The evidence gap, athlete risk, and clinic-marketing red flags.
MOTS-c UK legal status
The headline ‘longevity peptide’. Unlicensed in the UK, S0 in sport, and with marketing claims that run well ahead of the human-trial evidence base.
CJC-1295 UK legal status
CJC-1295 is a GHRH analogue, unlicensed in the UK, prohibited under WADA S2. The ‘CJC + ipamorelin’ stack, the ‘safer than HGH’ marketing, and what regulators see.
Ipamorelin UK legal status
GH secretagogue, unlicensed in the UK, prohibited under WADA S2. The selectivity argument doesn't change the regulatory or anti-doping position.
Tesamorelin UK legal status
Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy but unlicensed in the UK. ‘Visceral-fat reduction’ marketing extrapolates well beyond the licensed indication.
Sermorelin UK legal status
Sermorelin's original US licence was for paediatric GH-deficiency diagnostics. There is no UK marketing authorisation; the current ‘anti-ageing therapy’ marketing exceeds the historical indication and the evidence base.
Fake weight-loss pens and UK law
Counterfeit GLP-1 pens are a regulatory and criminal issue, not just a safety one. MHRA's role, advertising and supply offences, and where consumers fit in.
Online peptide sellers and UK law
How UK law treats online sellers — prescription-only medicine supply, advertising rules, pharmacy registration, and the unregulated 'research peptide' market.
Peptides and athletes (UK)
UK perspective on peptides in sport — WADA / UKAD framing, S0, strict liability, growth-hormone secretagogues, and what athletes should know before considering anything.
Peptides and gyms / personal trainers
What UK gyms, personal trainers, and coaches can and cannot lawfully say about peptides. CIMSPA / REPS scope, supply offences, advertising restrictions, and athlete-support-personnel rules.
Importing peptides into the UK
UK rules on personal import, prescription-only medicines from overseas, unlicensed compounds, and why customs is part of the framework rather than an obstacle to evade.
Social-media peptide ads (UK)
What Instagram, TikTok, YouTube, Facebook, Telegram and Snapchat content can lawfully say about peptides — HMR 2012 Part 12, CAP code, CPRs 2008, ASA case patterns, influencer and platform rules.
Peptide affiliate marketing risk (UK)
Affiliate links to peptide retailers are a dual-risk exposure — ASA / CMA disclosure under the CAP code and CPRs 2008, plus aiding unlawful supply under HMR 2012. The 'material connection' concept explained.
How we write these pages
Read UK regulatory methodology for the primary sources we rely on and what we will and won't claim. Spotted a UK regulatory statement that has gone stale? Send us a correction.